in the spotlightAdvocacyConnectionTheEvery day, nonprofit organizations work to improve patients’ lives. <strong>ASD</strong> <strong>Healthcare</strong>supports a range of these advocacy groups, including the ones featured here.We hope this list helps you discover and connect with the ones that can makea difference to you and the patients you serve.alpha-1foundation.orgtheevanfoundation.orgThe Alpha-1 Foundation is dedicated to providing theleadership and resources that will result in increasedresearch, improved health, worldwide detection and acure for Alpha-1.2937 SW 27th Ave, Suite 302Miami, FL 33133877.228.7321The Evan’s Victory Against Neuroblastoma (EVAN)Foundation supports research that will foster newtherapeutic options for kids currently in treatment for thisunderfunded cancer.19308 Penrod TerraceGermantown, MD 20874jmfworld.comneuropathyaction.orgThe Jeffery Model Foundation dedicates its efforts tothe early diagnosis, treatments and, ultimately, curesfor primary immunodeficiency diseases.780 Third AvenueNew York, NY 10017212.819.0200The Neuropathy Action Foundation helps neuropathypatients obtain the resources, information and toolsneeded to access individualized treatment that canimprove their quality of life.1304 S. Roxbury Drive, #303Los Angeles, CA 90035877.512.7262neuropathy.orgsaveonelife.netThe Neuropathy Association provides patient support andeducation, advocates for patients, and supports criticalresearch. It has a nationwide network of 135 support groupsand 15 neuropathy centers at prominent medical institutions.60 E 42nd Street, Suite 942New York, NY 10165212.692.0662Save One Life offers a bridge of hope for hemophiliapatients in developing countries by providing peoplein developed countries sponsorship opportunities foras little as $20 a month.68 East Main Street, Suite 204Georgetown, MA 01833978.352.765240 InsideOut
Rhophylac deliversPROTECTIONwith her in mindThe high purity you expect• >95% IgG• ≤3% nonspecific protein aggregates, allowing forintravenous (IV) administration 1• IgA content (below 5 mcg/mL)– Rhophylac is contraindicated in IgA-deficient patients withantibodies against IgA and a history of hypersensitivityThe rapid performance you want, withflexible administration for her• Choice of IV or IM administration• Higher peak serum levels with IV administration• Clearance of 99% of 15 mL Rh-positive RBCs in as little as 12 hourswith IV administrationThe safety she deserves• ChromaPlus manufacturing process uses 3 complementary virussafety steps: solvent detergent, ion-exchange chromatography,and nanofiltration– The risk of virus transmission cannot be completely eliminatedImportant Safety InformationRhophylac is indicated for suppression of rhesus (Rh) isoimmunization in:• Pregnancy and obstetric conditions in non-sensitized, Rh o (D)-negativewomen with an Rh-incompatible pregnancy, including routine antepartumand postpartum Rh prophylaxis and Rh prophylaxis in cases of obstetriccomplications, invasive procedures during pregnancy, or obstetricmanipulative procedures.• Incompatible transfusions in Rh o (D)-negative individuals transfusedwith blood components containing Rh o (D)-positive red blood cells.For suppression of Rh isoimmunization, Rhophylac can be administeredIM or IV.WARNING: INTRAVASCULAR HEMOLYSIS IN ITPThis warning does not apply to Rh o (D)-negative patients treatedfor the suppression of Rh isoimmunization.Intravascular hemolysis leading to death has been reported in Rh o (D)-positive patients treated for immune thrombocytopenic purpura(ITP) with Rh o (D) Immune Globulin Intravenous (Human) products.Intravascular hemolysis can lead to clinically compromising anemiaand multi-system organ failure, including acute respiratory distresssyndrome (ARDS). Serious complications, including severe anemia,acute renal insufficiency, renal failure, and disseminated intravascularcoagulation (DIC), have also been reported. Closely monitor patientstreated for ITP with Rhophylac in a healthcare setting for at least8 hours after administration. See full prescribing information forcomplete boxed warning.Reference: 1. Data on file. CSL Plasma.Rhophylac is contraindicated in individuals with known anaphylactic orsevere systemic reaction to human immune globulin products. Rhophylac iscontraindicated in IgA-defi cient patients with antibodies to IgA and a historyof hypersensitivity.Allergic or hypersensitivity reactions may occur with Rhophylac; early signsof hypersensitivity include generalized urticaria, chest tightness, wheezing,hypotension, and anaphylaxis.Rhophylac is derived from human plasma. The risk of transmission of infectiousagents, including viruses and, theoretically, the Creutzfeldt-Jakob disease (CJD)agent, cannot be completely eliminated.Suppression of Rh Isoimmunization: For postpartum use following an Rhincompatiblepregnancy, Rhophylac should not be given to the newborn infant.The most common adverse reactions in the suppression of Rh isoimmunizationwith Rhophylac are nausea, dizziness, headache, injection-site pain, and malaise.Immunoglobulin administration may transiently interfere with the immuneresponse to live virus vaccines, such as measles, mumps and rubella.Please see brief summary of full prescribing informationfor Rhophylac on adjacent page.Rhophylac is manufactured by CSL Behring AG and distributed by CSL Behring LLC.Rhophylac is a registered trademark of CSL Behring AG.©2011 CSL Behring LLC1020 First Avenue, PO Box 61501, King of Prussia, PA 19406-0901 USAwww.CSLBehring-us.com www.Rhophylac.com RHO11-11-0012 12/2011<strong>ASD</strong> <strong>Healthcare</strong> 41
Change language